Eos Energy Enterprises, Inc. Announces Proposed Convertible Senior Notes Offering GlobeNewswire May 29, 2025 EDISON, N.J., May 29, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2030 (the […]
(NASDAQ:EOSE), EDISON, N.J., May 29, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”) today announced that it has commenced a $75,000,000 common stock offering (the “Offering”). The Offering is being made pursuant to the Securities Act of 1933, as amended (the “Securities Act). The Company expects to grant the
The report “3D Printing Metals Marketby Metal Type (Titanium, Aluminum, Steel, Nickel & Cobalt, Other Metal Types), Form (Filaments, Powder), Technology (Powder Bed Fusion, Directed Energy Deposition, Binder Jetting, Metal Extrusion, Other Technologies), End-use Industry (Aerospace & Defense, Automotive, Medical & Dental, Other End-Use Industries), and Region – Global Forecast to 2030”,global 3D printing metals
Eos Energy Enterprises, Inc. Announces Proposed Offering of Common Stock GlobeNewswire May 29, 2025 EDISON, N.J., May 29, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”) today announced that it has commenced a $75,000,000 common stock offering (the “Offering”). The Offering is being made pursuant to the Securities Act
(NasdaqGM:KROS), Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders
(TSX:AGI),(NYSE:AGI), All amounts are in United States dollars, unless otherwise stated. TORONTO, May 29, 2025 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today announced that the Company's Board of Directors has declared a quarterly dividend of US$0.025 per common share. The Company has paid dividends for 16 consecutive years, including
(NYSE:BBWI), First quarter net sales up 3% to $1.4 billion, at the high end of the guidance range, and earnings per diluted share up 29% to $0.49, exceeding the high end of the guidance range Net sales performance driven by compelling innovation Company maintains 2025 net sales guidance of 1% to 3% growth and earnings
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring GlobeNewswire May 29, 2025 Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and
Alamos Gold Declares Quarterly Dividend GlobeNewswire May 29, 2025 All amounts are in United States dollars, unless otherwise stated. TORONTO, May 29, 2025 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today announced that the Company's Board of Directors has declared a quarterly dividend of US$0.025 per common share. The Company
Bath & Body Works Reports 2025 First Quarter Results and Maintains Fiscal Year 2025 Guidance GlobeNewswire May 29, 2025 First quarter net sales up 3% to $1.4 billion, at the high end of the guidance range, and earnings per diluted share up 29% to $0.49, exceeding the high end of the guidance range Net sales